Tétu P, et al. - In a cohort of patients with melanoma brain metastases (MBM) treated with immunotherapy or targeted therapy, researchers investigated how overall survival may be influenced by the use of combined radiotherapy (cRT). They used a French multicentric biobank, which prospectively enrolled unresectable stage III or IV melanoma, to obtain clinical data from 262 patients with MBM. They defined two groups: the cRT group consisting of patients receiving cRT and the no-cRT group, which included patients not receiving cRT. Participants were followed up for a median duration of 6.9 months, with median overall survival of 16.8 months in the cRT group and 6.9 months in no-cRT group. Overall, findings were suggestive of a possible association of cRT with a significant reduction of 40% in the risk of mortality in patients with MBM treated with systemic therapy.